Original language | English |
---|---|
Pages (from-to) | 499-502 |
Number of pages | 4 |
Journal | Journal of Thoracic Oncology |
Volume | 17 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2022 |
Keywords
- ADJUVANT CHEMOTHERAPY
- CELL LUNG-CANCER
- MULTICENTER
- OPEN-LABEL
- PREOPERATIVE CHEMOTHERAPY
- SINGLE-ARM
Access to Document
- 10.1016/j.jtho.2021.11.024Licence: Free access - publisher
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Thoracic Oncology, Vol. 17, No. 4, 04.2022, p. 499-502.
Research output: Contribution to journal › Editorial › Academic › peer-review
TY - JOUR
T1 - Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
AU - Hendriks, Lizza E L
AU - Remon, Jordi
AU - Reck, Martin
N1 - Funding Information: Disclosure: Dr. Hendriks reports no conflicts related to current manuscript and the following outside of current manuscript: research funding Roche Genentech , Boehringer Ingelheim , AstraZeneca (all institution, Takeda and BeiGene under negotiation); advisory board: Bristol-Myers Squibb , Eli Lilly, Roche Genentech , Pfizer , Takeda , Merck Sharp & Dohme , Boehringer Ingelheim , Amgen , Janssen (all institution, Roche one time self); speaker: Merck Sharp & Dohme , Eli Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech , Bayer , Eli Lilly (institution); local principal investigators of clinical trials: AstraZeneca , Novartis , Bristol-Myers Squibb , Merck Sharp & Dohme / Merck , GlaxoSmithKline , Takeda , Blueprint Medicines, Roche Genentech , Janssen Pharmaceuticals , Mirati. Dr. Remon reports no conflicts related to current manuscript and the following outside of current manuscript: advisory board: Merck Sharp & Dohme, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Roche; Bayer. speaker: Pfizer; travel reimbursement: OSE Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, Roche. Dr. Reck reports no conflicts related to current manuscript and the following outside of current manuscript: honoraria for lectures and consultancy from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, BeiGene, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp & Dohme, Eli Lilly, Novartis, Pfizer, Roche, and Sanofi. Funding Information: Disclosure: Dr. Hendriks reports no conflicts related to current manuscript and the following outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim, AstraZeneca (all institution, Takeda and BeiGene under negotiation); advisory board: Bristol-Myers Squibb, Eli Lilly, Roche Genentech, Pfizer, Takeda, Merck Sharp & Dohme, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: Merck Sharp & Dohme, Eli Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech, Bayer, Eli Lilly (institution); local principal investigators of clinical trials: AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati. Dr. Remon reports no conflicts related to current manuscript and the following outside of current manuscript: advisory board: Merck Sharp & Dohme, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Roche; Bayer. speaker: Pfizer; travel reimbursement: OSE Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, Roche. Dr. Reck reports no conflicts related to current manuscript and the following outside of current manuscript: honoraria for lectures and consultancy from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, BeiGene, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp & Dohme, Eli Lilly, Novartis, Pfizer, Roche, and Sanofi.
PY - 2022/4
Y1 - 2022/4
KW - ADJUVANT CHEMOTHERAPY
KW - CELL LUNG-CANCER
KW - MULTICENTER
KW - OPEN-LABEL
KW - PREOPERATIVE CHEMOTHERAPY
KW - SINGLE-ARM
U2 - 10.1016/j.jtho.2021.11.024
DO - 10.1016/j.jtho.2021.11.024
M3 - Editorial
C2 - 35307106
SN - 1556-0864
VL - 17
SP - 499
EP - 502
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 4
ER -